Navigation Links
Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Date:12/13/2007

uticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about the continuation of the Phase 3 program and development of lorcaserin, the significance of the inclusion in the BLOSSOM and BLOOM-DM trials of patients with FDA-defined valvulopathy and, in the case of the BLOOM-DM trial, with type 2 diabetes, the significance of the review of echocardiographic data, the timing of the Echocardiographic Safety Monitoring Board's month 12 review of echocardiographic data, the rate of valvulopathy in the BLOOM trial, the number of patients in the Phase 3 lorcaserin clinical trials, the timing, number, protocol, design, scope, cost and other aspects of the lorcaserin trials and studies, the completeness and usefulness of the expected database of lorcaserin data in exploring, evaluating and understanding lorcaserin, the growth and impact of obesity, the need for new treatment options to address obesity, the ability of lorcaserin to fulfill such need, the ability of data to support the use of lorcaserin, the tolerability, side effects, efficacy and the commercial and other potential of lorcaserin, the breadth of Arena's pipeline, Arena's strategy, preclinical and internal and partnered clinical programs, and about Arena's ability to develop compounds and commercialize drugs and other statements that are not historical facts. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's planned clinical trials and studies may not proceed at t
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
(Date:12/24/2014)... , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: ... areas, announced the closing of an underwritten public offering of ... to an aggregate 3,500,000 shares of common stock, at an ... The warrants have a per share exercise price of $5.00, ...
(Date:12/24/2014)... 2014 GMO corn cases filed across the ... the process of being consolidated in a Kansas federal court ... AG MIR 162 Corn Litigation, MDL No. 2591 in the ... of the Syngenta GMO corn multidistrict litigation (MDL) has been ...
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3
... Products Industry Leader, DEERFIELD, Ill., Sept. 12 ... it has been named 2007,Medical Products Industry Leader of ... Dow Jones Sustainability North America Index,(DJSI North America). This ... listed in the DJSI and the sixth year the ...
... 12 Leading scientists,from around the world will ... approaches for producing life-saving vaccines and,antibodies. More than ... "New Cells for New Vaccines II: Focus on ... du Pont. The international,scientific workshop is being organized ...
... 12 Human Pheromone,Sciences, Inc. (OTC Bulletin Board: ... of an exclusive Agency Agreement with Brand,Intelligence Group, ... Attraction(R) brand, which contains its proprietary and patented,human ... Agreement, HPS and BIG will work together to,develop ...
Cached Biology Technology:Baxter Named to Dow Jones Sustainability Index for Ninth Consecutive Year 2International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development 2Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand 2
(Date:1/22/2015)... 22, 2015   EyeLock, Inc. , a market leader of ... Steve Gerber to the new role of Senior Vice ... leading development of mobile platforms and wearable solutions for EyeLock,s ... innovation in the semiconductor industry to his role at EyeLock, ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... Inc., the leading personal genetics company, today announced the publication ... of individuals from across the United States ... hundred years ago, the United States ... continents. This study illuminates how American history and the ongoing ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2The Global Watermarking and Fingerprinting Markets 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... Discovery Fund (LSDF) today announced $1.1 million in ... and non-profit organizations to foster the translation of ... marketplace. Two of the five new ... invented within Washington-based companies. HeatFlow Technologies (principal investigator ...
... Researchers at Queen Mary University of London have shown for ... on to perform is controlled by primary cilia tiny hair-like ... of becoming any cell type within the body through the ... for application in the development of new therapies for a ...
... has known for years that people who drink moderate amounts ... general, they are healthier and have better cardiovascular function that ... research from Oregon Health & Science University adds a fascinating ... help it fight off infection. The research, published Dec. ...
Cached Biology News:Life Sciences Discovery Fund announces R&D grants 2Study: Moderate alcohol consumption boosts body's immune system 2Study: Moderate alcohol consumption boosts body's immune system 3
...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Antibody Diluent for IHC 125 ml...
QPRT Antibody...
Biology Products: